Inhibitory effect of LXR activation on cell proliferation and cell cycle progression through lipogenic activity

Journal of Lipid Research

Volumn 51, Issue 12, 2010, Pages 3425-3433

  Kim, Kang Ho ^a   Lee, Gha Young ^a   Kim, Jong In ^a   Ham, Mira ^a   Lee, Joo Won ^a   Kim, Jae Bum ^a  

^a Seoul National University   (South Korea)

Author keywords

Fatty acid synthesis; Ligand; Liver X receptor

Indexed keywords

3 [3 [[2 CHLORO 3 (TRIFLUOROMETHYL)BENZYL](2 DIPHENYLETHYL)AMINO]PROPOXY]PHENYLACETIC ACID; FAS ANTIGEN; LIVER X RECEPTOR; N (2,2,2 TRIFLUOROETHYL) N [4 [2,2,2 TRIFLUORO 1 HYDROXY 1 (TRIFLUOROMETHOXY)ETHYL]PHENYL]BENZENESULFONAMIDE; SMALL INTERFERING RNA; TRIACYLGLYCEROL;

ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN HEK293; CELL STRAIN HEPG2; CELL STRAIN LNCAP; CELL TYPE; CONTROLLED STUDY; GENE EXPRESSION; GROWTH INHIBITION; HELA CELL; HUMAN; HUMAN CELL; LIPOGENESIS; PRIORITY JOURNAL;

BENZOIC ACIDS; BENZYLAMINES; CELL CYCLE; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACIDS; HUMANS; HYDROCARBONS, FLUORINATED; LIGANDS; LIPOGENESIS; ORPHAN NUCLEAR RECEPTORS; SULFONAMIDES; TUMOR CELLS, CULTURED;

EID: 78650043469     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M007989     Document Type: Article

References (46)

1. Steffensen, K. R., and J. A. Gustafsson. 2004. Putative metabolic effects of the liver X receptor (LXR). Diabetes. 53 (Suppl. 1): S36-S42.
2. Annicotte, J. S., K. Schoonjans, and J. Auwerx. 2004. Expression of the liver X receptor alpha and beta in embryonic and adult mice. Anat. Rec. A Discov. Mol. Cell. Evol. Biol. 277: 312-316.
3. Janowski, B. A., P. J. Willy, T. R. Devi, J. R. Falck, and D. J. Mangelsdorf. 1996. An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature. 383: 728-731.
4. Peet, D. J., S. D. Turley, W. Ma, B. A. Janowski, J. M. Lobaccaro, R. E. Hammer, and D. J. Mangelsdorf. 1998. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell. 93: 693-704.
5. Repa, J. J., and D. J. Mangelsdorf. 2002. The liver X receptor gene team: potential new players in atherosclerosis. Nat. Med. 8: 1243-1248.
6. Naik, S. U., X. Wang, J. S. Da Silva, M. Jaye, C. H. Macphee, M. P. Reilly, J. T. Billheimer, G. H. Rothblat, and D. J. Rader. 2006. Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. Circulation. 113: 90-97.
7. Plosch, T., T. Kok, V. W. Bloks, M. J. Smit, R. Havinga, G. Chimini, A. K. Groen, and F. Kuipers. 2002. Increased hepatobiliary and fecal cholesterol excretion upon activation of the liver X receptor is independent of ABCA1. J. Biol. Chem. 277: 33870-33877.
8. Ohashi, R., H. Mu, Q. Yao, and C. Chen. 2004. Cellular and molecular mechanisms of atherosclerosis with mouse models. Trends Cardiovasc. Med. 14: 187-190.
9. Tangirala, R. K., E. D. Bischoff, S. B. Joseph, B. L. Wagner, R. Walczak, B. A. Laffitte, C. L. Daige, D. Thomas, R. A. Heyman, D. J. Mangelsdorf, et al. 2002. Identification of macrophage liver X receptors as inhibitors of atherosclerosis. Proc. Natl. Acad. Sci. USA. 99: 11896-11901.
10. Darimont, C., O. Avanti, I. Zbinden, P. Leone-Vautravers, R. Mansourian, V. Giusti, and K. Mace. 2006. Liver X receptor preferentially activates de novo lipogenesis in human preadipocytes. Biochimie. 88: 309-318.
11. Joseph, S. B., B. A. Laffitte, P. H. Patel, M. A. Watson, K. E. Matsukuma, R. Walczak, J. L. Collins, T. F. Osborne, and P. Tontonoz. 2002. Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors. J. Biol. Chem. 277: 11019-11025.
12. Yoshikawa, T., H. Shimano, M. Amemiya-Kudo, N. Yahagi, A. H. Hasty, T. Matsuzaka, H. Okazaki, Y. Tamura, Y. Iizuka, K. Ohashi, et al. 2001. Identification of liver X receptor-retinoid X receptor as an activator of the sterol regulatory element-binding protein 1c gene promoter. Mol. Cell. Biol. 21: 2991-3000.
13. Choe, S. S., A. H. Choi, J. W. Lee, K. H. Kim, J. J. Chung, J. Park, K. M. Lee, K. G. Park, I. K. Lee, and J. B. Kim. 2007. Chronic activation of liver X receptor induces beta-cell apoptosis through hyperactivation of lipogenesis: liver X receptor-mediated lipotoxicity in pancreatic beta-cells. Diabetes. 56: 1534-1543.
14. Collins, J. L., A. M. Fivush, M. A. Watson, C. M. Galardi, M. C. Lewis, L. B. Moore, D. J. Parks, J. G. Wilson, T. K. Tippin, J. G. Binz, et al. 2002. Identification of a nonsteroidal liver X receptor agonist through parallel array synthesis of tertiary amines. J. Med. Chem. 45: 1963-1966.
15. Joseph, S. B., A. Castrillo, B. A. Laffitte, D. J. Mangelsdorf, and P. Tontonoz. 2003. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat. Med. 9: 213-219.
16. Joseph, S. B., M. N. Bradley, A. Castrillo, K. W. Bruhn, P. A. Mak, L. Pei, J. Hogenesch, R. M. O'Connell, G. Cheng, E. Saez, et al. 2004. LXR-dependent gene expression is important for macrophage survival and the innate immune response. Cell. 119: 299-309.
17. Blaschke, F., O. Leppanen, Y. Takata, E. Caglayan, J. Liu, M. C. Fishbein, K. Kappert, K. I. Nakayama, A. R. Collins, E. Fleck, et al. 2004. Liver X receptor agonists suppress vascular smooth muscle cell proliferation and inhibit neointima formation in ballooninjured rat carotid arteries. Circ. Res. 95: e110-e123.
18. Wente, W., M. B. Brenner, H. Zitzer, J. Gromada, and A. M. Efanov. 2007. Activation of liver X receptors and retinoid X receptors induces growth arrest and apoptosis in insulin-secreting cells. Endocrinology. 148: 1843-1849.
19. Chuu, C. P., R. A. Hiipakka, J. M. Kokontis, J. Fukuchi, R. Y. Chen, and S. Liao. 2006. Inhibition of tumor growth and progression of LNCaP prostate cancer cells in athymic mice by androgen and liver X receptor agonist. Cancer Res. 66: 6482-6486.
20. Fukuchi, J., J. M. Kokontis, R. A. Hiipakka, C. P. Chuu, and S. Liao. 2004. Antiproliferative effect of liver X receptor agonists on LNCaP human prostate cancer cells. Cancer Res. 64: 7686-7689.
21. Meng, Z. X., J. Nie, J. J. Ling, J. X. Sun, Y. X. Zhu, L. Gao, J. H. Lv, D. Y. Zhu, Y. J. Sun, and X. Han. 2009. Activation of liver X receptors inhibits pancreatic islet beta cell proliferation through cell cycle arrest. Diabetologia. 52: 125-135.
22. Choi, M., S. Rolle, M. Rane, H. Haller, F. C. Luft, and R. Kettritz. 2003. Extracellular signal-regulated kinase inhibition by statins inhibits neutrophil activation by ANCA. Kidney Int. 63: 96-106. (Pubitemid 35463910)
23. Wagner, A. H., M. Gebauer, B. Guldenzoph, and M. Hecker. 2002. 3-hydroxy-3-methylglutaryl coenzyme A reductase-independent inhibition of CD40 expression by atorvastatin in human endothelial cells. Arterioscler. Thromb. Vasc. Biol. 22: 1784-1789.
24. Kim, K. H., S. H. Choi, T. S. Lee, W. K. Oh, D. S. Kim, and J. B. Kim. 2006. Selective LXRalpha inhibitory effects observed in plant extracts of MEH184 (Parthenocissua tricuspidata) and MEH185 (Euscaphis japonica). Biochem. Biophys. Res. Commun. 349: 513-518.
25. Houck, K. A., K. M. Borchert, C. D. Hepler, J. S. Thomas, K. S. Bramlett, L. F. Michael, and T. P. Burris. 2004. T0901317 is a dual LXR/FXR agonist. Mol. Genet. Metab. 83: 184-187.
26. Mitro, N., L. Vargas, R. Romeo, A. Koder, and E. Saez. 2007. T0901317 is a potent PXR ligand: implications for the biology ascribed to LXR. FEBS Lett. 581: 1721-1726.
27. Bensinger, S. J., M. N. Bradley, S. B. Joseph, N. Zelcer, E. M. Janssen, M. A. Hausner, R. Shih, J. S. Parks, P. A. Edwards, B. D. Jamieson, et al. 2008. LXR signaling couples sterol metabolism to proliferation in the acquired immune response. Cell. 134: 97-111.
28. Kim, J. B., P. Sarraf, M. Wright, K. M. Yao, E. Mueller, G. Solanes, B. B. Lowell, and B. M. Spiegelman. 1998. Nutritional and insulin regulation of fatty acid synthetase and leptin gene expression through ADD1/SREBP1. J. Clin. Invest. 101: 1-9.
29. Kim, J. B., and B. M. Spiegelman. 1996. ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism. Genes Dev. 10: 1096-1107.
30. Tontonoz, P., J. B. Kim, R. A. Graves, and B. M. Spiegelman. 1993. ADD1: a novel helix-loop-helix transcription factor associated with adipocyte determination and differentiation. Mol. Cell. Biol. 13: 4753-4759.
31. Kim, K. H., M. J. Song, E. J. Yoo, S. S. Choe, S. D. Park, and J. B. Kim. 2004. Regulatory role of glycogen synthase kinase 3 for transcriptional activity of ADD1/SREBP1c. J. Biol. Chem. 279: 51999-52006.
32. Menendez, J. A., L. Vellon, I. Mehmi, B. P. Oza, S. Ropero, R. Colomer, and R. Lupu. 2004. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. Proc. Natl. Acad. Sci. USA. 101: 10715-10720.
33. Thupari, J. N., M. L. Pinn, and F. P. Kuhajda. 2001. Fatty acid synthase inhibition in human breast cancer cells leads to malonyl-CoA-induced inhibition of fatty acid oxidation and cytotoxicity. Biochem. Biophys. Res. Commun. 285: 217-223.
34. Kuhajda, F. P., E. S. Pizer, J. N. Li, N. S. Mani, G. L. Frehywot, and C. A. Townsend. 2000. Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc. Natl. Acad. Sci. USA. 97: 3450-3454.
35. Okawa, Y., T. Hideshima, H. Ikeda, N. Raje, S. Vallet, T. Kiziltepe, H. Yasui, S. Enatsu, S. Pozzi, I. Breitkreutz, et al. 2008. Fatty acid synthase is a novel therapeutic target in multiple myeloma. Br. J. Haematol. 141: 659-671.
36. Chuu, C. P., J. M. Kokontis, R. A. Hiipakka, and S. Liao. 2007. Modulation of liver X receptor signaling as novel therapy for prostate cancer. J. Biomed. Sci. 14: 543-553.
37. Aronis, A., Z. Madar, and O. Tirosh. 2008. Lipotoxic effects of triacylglycerols in J774.2 macrophages. Nutrition. 24: 167-176.
38. Malhi, H., S. F. Bronk, N. W. Werneburg, and G. J. Gores. 2006. Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. J. Biol. Chem. 281: 12093-12101.
39. Feldstein, A. E., N. W. Werneburg, A. Canbay, M. E. Guicciardi, S. F. Bronk, R. Rydzewski, L. J. Burgart, and G. J. Gores. 2004. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology. 40: 185-194.
40. Wrede, C. E., L. M. Dickson, M. K. Lingohr, I. Briaud, and C. J. Rhodes. 2002. Protein kinase B/Akt prevents fatty acid-induced apoptosis in pancreatic beta-cells (INS-1). J. Biol. Chem. 277: 49676-49684.
41. Bollheimer, L. C., R. H. Skelly, M. W. Chester, J. D. McGarry, and C. J. Rhodes. 1998. Chronic exposure to free fatty acid reduces pancreatic beta cell insulin content by increasing basal insulin secretion that is not compensated for by a corresponding increase in proinsulin biosynthesis translation. J. Clin. Invest. 101: 1094-1101.
42. Yam, C. H., T. K. Fung, and R. Y. Poon. 2002. Cyclin A in cell cycle control and cancer. Cell. Mol. Life Sci. 59: 1317-1326.
43. De Boer, L., V. Oakes, H. Beamish, N. Giles, F. Stevens, M. Somodevilla-Torres, C. Desouza, and B. Gabrielli. 2008. Cyclin A/cdk2 coordinates centrosomal and nuclear mitotic events. Oncogene. 27: 4261-4268.
44. Girard, F., U. Strausfeld, A. Fernandez, and N. J. Lamb. 1991. Cyclin A is required for the onset of DNA replication in mammalian fibroblasts. Cell. 67: 1169-1179.
45. Katich, S. C., K. Zerfass-Thome, and I. Hoffmann. 2001. Regulation of the Cdc25A gene by the human papillomavirus Type 16 E7 oncogene. Oncogene. 20: 543-550. (Pubitemid 32156178)
46. Sexl, V., J. A. Diehl, C. J. Sherr, R. Ashmun, D. Beach, and M. F. Roussel. 1999. A rate limiting function of cdc25A for S phase entry inversely correlates with tyrosine dephosphorylation of Cdk2. Oncogene. 18: 573-582.